Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of spesolimab in generalized pustular psoriasis
jRCT2041210087Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started Nov 2021; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on jRCT2041210087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210087.